Business
BillionToOne Reports Third Quarter 2025 Results
MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2025 and initiated guidance for the remainder of 2025. Recent Financial Highlights: Total revenue of $83.5 million in the third quarter of 2025, compared to $38.4 million in the third quarter of 2024, an
About this update from Billiontoone, Inc.
[{"type":"image","alt":"BillionToOne, Inc.","displaySize":"","headline":null,"caption":"BillionToOne, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":158,"url":"https://media.zenfs.com/en/globenewswire.com/a8773d444a4068c16414f95fd9063401"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rXKo9dBLUOvPQyzwoqhIZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a8773d444a4068c16414f95fd9063401","width":300,"height":158}},"lazy":false},{"type":"text","content":"MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2025 and initiated guidance for the remainder of 2025.","length":351,"tagName":"p"},{"type":"text","content":"Recent Financial Highlights:","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue of $83.5 million in the third quarter of 2025, compared to $38.4 million in the third quarter of 2024, an increase of 117%.","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Prenatal clinical testing revenue was $74.1 million in the third quarter of 2025, an increase of 102% from the third quarter last year.","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"Oncology clinical testing revenue was $8.7 million in the third quarter of 2025, which represents an increase of 7.6x compared to $1.1 million in the same period last year and a 76% sequential quarter over quarter increase from $4.9 million in the second quarter of 2025.","length":271,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross margin was 70% in the third quarter of 2025, compared to 53% in the third quarter of 2024, a 17 percentage-point increase year over year.","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"162,900 tests accessioned in the third quarter of 2025, compared to 107,900 tests accessioned in the third quarter of 2024, an increase of 51%.","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating income of $9.6 million in the third quarter of 2025, compared to a ($12.6) million operating loss in the third quarter of 2024.","length":137,"tagName"...